• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 5th March 2021

Does Government Funding Increase Public Sector Development of New Medicines?

A new paper, published last week in Applied Economics, by Dimitrios Kourouklis, Senior Economist at OHE, looks at the question of whether government funding increases public sector development of new medicines. Looking at public sector drug development in Europe, this…

Dimitrios-2-scaled-1
Dimitrios Kourouklis
Isobel Firth
Isobel Firth
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A new paper, published last week in Applied Economics, by Dimitrios Kourouklis, Senior Economist at OHE, looks at the question of whether government funding increases public sector development of new medicines. Looking at public sector drug development in Europe, this paper suggests that government funding does have an impact on the research and development pipeline, particularly at the earlier stages of research for medicines targeting rare diseases.

To answer this question, a paper published last week by Dimitrios Kourouklis (2021), Senior Economist at OHE, quantifies the effect of public subsidies for research and development (R&D) on public sector drug development. He estimates the impact across different stages of the pharmaceutical R&D process from basic research to Phase 1 (first safety trials in healthy humans) and to Phase 3 (large clinical trials in patients). He also looks at how the effect of public investment varies for rare diseases (so-called ‘orphan’ drugs) compared to non-rare diseases.

Pharmaceutical research and development (R&D) spending is increasing. In 2015, the total amount of money spent on R&D worldwide was 150 billion USD1 (IFPMA 2017). The amount of investment in R&D varies across disease areas, based on their profitability, their burden of disease, and how risky drug development is in that disease area.2,3 This variation means that incentives do not always encourage commercial investment in R&D for the diseases or technologies reflecting societal needs.4 For example, there is a lack of commercial incentive to invest in vaccines despite there being a great need for them worldwide.5

To compensate for the potential gaps in private research funding, governments directly invest in pharmaceutical R&D particularly supporting drug development outside pharmaceutical companies in public institutions. Although poorly complied with, since 2000 the European member states pledged under the Lisbon strategy to invest 3% of GDP on funding R&D. According to data from the World Bank in 2018, countries in the EU spent an average of 2.18% of GDP (€327 billion) on R&D.6 Given the huge sums of public money that are invested in R&D, we need to know: does it actually work in the context of public sector drug development?

This study finds that public funding does increase pharmaceutical R&D in public institutions. However, the effect varies depending on where in the R&D pipeline you look. A 1% increase in public subsidies causes an increase of 0.11% in Phase 1 clinical trials for publicly developed non-orphan drugs, and also stimulates basic research (by 1.41%), Phase 1 (by 0.04%) and Phase 2 (by 0.12%) clinical trials for publicly developed orphan drugs for rare diseases.

The results imply that public policies such as subsidizing R&D do have important effects on the number of drugs in development from universities and other public sector institutions. Also, these estimates are likely to be attributed to the fact that governments tend to finance R&D for basic research and early stages of innovation. Overall, the results suggest that public financing R&D increases the number of drugs moving through the R&D pipeline, particularly for rare diseases.

If you are interested in this topic, you can find OHE’s related publications on our research theme The Economics of Innovation listed below.

Citation

Kourouklis, D., 2021. Public subsidies for R&D and public sector pharmaceutical innovation. Applied Economics, pp.1–19. 10.1080/00036846.2021.1885614.

  1. IFPMA., 2017. The Pharmaceutical Industry and Global Health: Facts and Figures 2017. (downloaded from https://www.ifpma.org/wp-content/uploads/2017/02/IFPMA-Facts-And-Figures-2017.pdf)
  2. Barrenho, E. and Miraldo, M., 2018. R&D Success in Pharmaceutical Markets: A Duration Model Approach. In: Health Econometrics, Contributions to Economic Analysis. [online] Emerald Publishing Limited, pp.201–233. 10.1108/S0573-855520180000294010.
  3. Barrenho, E., Miraldo, M. and Smith, P.C., 2019. Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries. Health Economics, 28(1), pp.123–143. https://doi.org/10.1002/hec.3833.
  4. Danzon, P.M. and Towse, A., 2003. Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents. International Journal of Health Care Finance and Economics, 3(3), pp.183–205. 10.1023/A:1025384819575.
  5. Glennerster, R., M. Kremer, and H. Williams. 2006. “Creating Markets for Vaccines.” Innovations: Technology,  Governance, Globalization 1 (1): 67–79. doi:10.1162/ itgg.2006.1.1.67.
  6. World Bank. Research and Development expenditure (% GDP). Available from: https://data.worldbank.org/indicator/GB.XPD.RSDV.GD.ZS?name_desc=false. [Accessed: March 3, 2021)

Related Research

Berdud, M., Drummond, M. and Towse, A., 2020. Establishing a reasonable price for an orphan drug. Cost Effectiveness and Resource Allocation, 18(1), p.31. 10.1186/s12962-020-00223-x.

Brassel, S. and Cookson, G., 2020. Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies. [online] Available at: https://www.ohe.org/publications/delivering-24-percent-unlocking-uk-pharma-rd-investment-through-evidence-based-policies [Accessed 3 Mar. 2021].

Kourouklis, D., 2021. Public subsidies for R&D and public sector pharmaceutical innovation. Applied Economics, pp.1–19. 10.1080/00036846.2021.1885614.

Mestre-Ferrandiz, J., Sussex, J. and Towse, A., 2012. The R&D Cost of a New Medicine. [online] Office of Health Economics. Available at: https://ideas.repec.org/b/ohe/monogr/000135.html [Accessed 27 Feb. 2021].

Towse, A. and Sharma, P., 2011. Incentives for R&D for New Antimicrobial Drugs. International Journal of the Economics of Business, 18(2), pp.331–350. 10.1080/13571516.2011.584434.

  • Drug Development/R&D
  • Economics of Innovation
  • Europe

Related Insights

Eye-Disease Gene-Therapies blog
  • Insight
  • February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Read more
Fishing on the lake at sunset. Fishing background.
  • Insight
  • February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Read more
Cancer_WellcomeCollection_landscape
  • Insight
  • January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Read more
G7Antibiotics_blog_featuredimage
  • Insight
  • December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!